To establish diagnostic criteria for ductal adenocarcinomas of the pancreas (PCs), bacterial artificial chromosome (BAC) array-based methylated CpG island amplification was performed using 139 tissue samples. Twelve BAC clones, for which DNA methylation status was able to discriminate cancerous tissue (T) from noncancerous pancreatic tissue in the learning cohort with a specificity of 100, were identified. Using criteria that combined the 12 BAC clones, T-samples were diagnosed as cancers with 100 sensitivity and specificity in both the learning and validation cohorts. DNA methylation status on 11 of the BAC clones, which was able to discriminate patients showing early relapse from those with no relapse in the learning cohort with 100 specificity, was correlated with the recurrence-free and overall survival rates in the validation cohort and was an independent prognostic factor by multivariate analysis. Genome-wide DNA methylation profiling may provide optimal diagnostic markers and prognostic indicators for patients with PCs. © 2011 Masahiro Gotoh et al.
CITATION STYLE
Kanai, Y., Gotoh, M., Arai, E., Wakai-Ushijima, S., Hiraoka, N., Kosuge, T., … Inazawa, J. (2011). Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification. Journal of Biomedicine and Biotechnology, 2011. https://doi.org/10.1155/2011/780836
Mendeley helps you to discover research relevant for your work.